1-45509214-G-T
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM4BP6BS1BS2
The NM_015506.3(MMACHC):c.848G>T(p.Ter283LeuextTer14) variant causes a stop lost change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00023 in 1,613,930 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. *283*) has been classified as Likely benign.
Frequency
Consequence
NM_015506.3 stop_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MMACHC | NM_015506.3 | c.848G>T | p.Ter283LeuextTer14 | stop_lost | 4/4 | ENST00000401061.9 | |
MMACHC | NM_001330540.2 | c.677G>T | p.Ter226LeuextTer14 | stop_lost | 4/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MMACHC | ENST00000401061.9 | c.848G>T | p.Ter283LeuextTer14 | stop_lost | 4/4 | 2 | NM_015506.3 | P1 | |
MMACHC | ENST00000616135.1 | c.677G>T | p.Ter226LeuextTer14 | stop_lost | 4/5 | 2 |
Frequencies
GnomAD3 genomes AF: 0.000289 AC: 44AN: 152026Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00112 AC: 277AN: 248412Hom.: 4 AF XY: 0.000756 AC XY: 102AN XY: 135006
GnomAD4 exome AF: 0.000224 AC: 328AN: 1461786Hom.: 4 Cov.: 32 AF XY: 0.000157 AC XY: 114AN XY: 727188
GnomAD4 genome AF: 0.000289 AC: 44AN: 152144Hom.: 0 Cov.: 32 AF XY: 0.000309 AC XY: 23AN XY: 74382
ClinVar
Submissions by phenotype
Cobalamin C disease Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 10, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 30, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | - - |
not provided Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 26, 2015 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 08, 2021 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 24, 2022 | Variant summary: MMACHC c.848G>T (p.X283LeuextX14) changes the termination codon and is predicted to lead to an extended protein with additional amino acids added to the normal C-terminus. MMACHC c.848G>T (p.X283LeuextX14) causes a frameshift which results in an extension of the protein. The variant allele was found at a frequency of 0.0011 in 248412 control chromosomes, predominantly at a frequency of 0.008 within the Latino subpopulation in the gnomAD database, including 4 homozygotes. The observed variant frequency within Latino control individuals in the gnomAD database is approximately 3 fold of the estimated maximal expected allele frequency for a pathogenic variant in MMACHC causing Methylmalonic Acidemia With Homocystinuria phenotype (0.0032), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Latino origin. To our knowledge, no occurrence of c.848G>T in individuals affected with Methylmalonic Acidemia With Homocystinuria and no experimental evidence demonstrating its impact on protein function have been reported. Five ClinVar submitters (evaluation after 2014) cite the variant as benign (n=3) and uncertain significance (n=2). Based on the evidence outlined above, the variant was classified as benign. - |
MMACHC-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 23, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Methylmalonic acidemia with homocystinuria cblC Benign:1
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Apr 30, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at